Codiak BioSciences, Inc.
DelistedCIK 1659352fmd_1QV5YNCJWQ3EW5FCGTF0462QJ8Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2022, 13 periods
| Line item | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Total revenues | 0 | 3 | 23 |
| Research and development | 60 | 74 | 65 |
| Total operating expenses | 81 | 94 | 92 |
| Operating income | (80) | (91) | (70) |
| Interest expense | 0 | 2 | 3 |
| Interest and investment income | 2 | 0 | 0 |
| Other non-operating income (expense) | 2 | (1) | 32 |
| Income tax expense | 0 | 0 | 0 |
| Net income | (78) | (92) | (37) |
| Net income to common shareholders | (92) | (102) | (37) |